- Home
- TNXP vs CWD Comparison
TNXP vs CWD Comparison
Compare TNXP & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- CWD
- Stock Information
- Founded
- TNXP 2007
- CWD 2009
- Country
- TNXP United States
- CWD United States
- Employees
- TNXP N/A
- CWD N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- TNXP Health Care
- CWD Finance
- Exchange
- TNXP Nasdaq
- CWD Nasdaq
- Market Cap
- TNXP 15.1M
- CWD 13.4M
- IPO Year
- TNXP N/A
- CWD 2023
- Fundamental
- Price
- TNXP $0.14
- CWD $0.54
- Analyst Decision
- TNXP Strong Buy
- CWD
- Analyst Count
- TNXP 2
- CWD 0
- Target Price
- TNXP $53.50
- CWD N/A
- AVG Volume (30 Days)
- TNXP 26.1M
- CWD 92.1K
- Earning Date
- TNXP 11-07-2024
- CWD 11-07-2024
- Dividend Yield
- TNXP N/A
- CWD N/A
- EPS Growth
- TNXP N/A
- CWD N/A
- EPS
- TNXP N/A
- CWD N/A
- Revenue
- TNXP $12,458,000.00
- CWD $72,100,000.00
- Revenue This Year
- TNXP $62.53
- CWD N/A
- Revenue Next Year
- TNXP $26.17
- CWD $41.65
- P/E Ratio
- TNXP N/A
- CWD N/A
- Revenue Growth
- TNXP N/A
- CWD N/A
- 52 Week Low
- TNXP $0.12
- CWD $0.50
- 52 Week High
- TNXP $22.08
- CWD $1.74
- Technical
- Relative Strength Index (RSI)
- TNXP 30.04
- CWD 39.65
- Support Level
- TNXP $0.14
- CWD $0.51
- Resistance Level
- TNXP $0.21
- CWD $0.76
- Average True Range (ATR)
- TNXP 0.02
- CWD 0.07
- MACD
- TNXP 0.02
- CWD -0.01
- Stochastic Oscillator
- TNXP 22.89
- CWD 12.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.